Hypereosinophilic Syndromes

Also known as: Hypereosinophilic syndrome

DrugDrug NameDrug Description
DB01005HydroxyureaAn antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. [PubChem]
DB00619ImatinibImatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
DrugDrug NamePhaseStatusCount
DB06612Mepolizumab1 / 2Completed1
DB04868Nilotinib1 / 2Completed1
DB12023Benralizumab2Recruiting1
DB01254Dasatinib2Completed1
DB00619Imatinib2Completed2
DB00619Imatinib2Recruiting1
DB00619Imatinib2Terminated1
DB00619Imatinib2Withdrawn1
DB06612Mepolizumab2Completed1
DB06612Mepolizumab3Not Yet Recruiting1
DB06612Mepolizumab3Recruiting1
DB06612Mepolizumab3Terminated1
DB00619ImatinibNot AvailableCompleted1
DB06612MepolizumabNot AvailableAvailable1